ALNY has clawed back 20% in a month to $246, yet the gap between where the stock trades and where analysts think it should be remains the defining tension heading into October earnings.
The recovery since the August lows is real. ALNY closed at $246.11, up 2.5% on the week and nearly 20% over the past month. That is a meaningful bounce from the post-earnings wreckage — the July 30 print sent the stock down 28% in a session, and the August 6 release added another 4% loss. Even with the rebound, the stock is still dramatically below where most of the Street has its models pegged. The consensus target has been trimmed hard — Wells Fargo cut to $256 from $316, Citi cut to $340 from $380, Barclays to $450 from $527, and JP Morgan to $375 from $400, all in the aftermath of those two prints. Yet the direction of ratings hasn't moved: 15 buys, no downgrades. Raymond James went the other way entirely, upgrading to Strong Buy. BMO initiated fresh coverage at Outperform with a $318 target. HC Wainwright, reiterating this week, holds a $455 target. The range is wide — from Wells Fargo's $256 to HC Wainwright's $455 — and that spread itself tells the story. The Street sees roughly 50% upside on average, but there is genuine disagreement about how fast AMVUTTRA commercial revenue can recover and whether the pipeline justifies premium-biotech multiples at this price.
Positioning around the stock is loose rather than charged. Short interest has been drifting lower all month, falling roughly 9% over the past 30 days to 3.9% of free float — a level that is moderate and declining, not a source of pressure in either direction. Borrowing ALNY costs almost nothing: the cost to borrow has eased to around 0.41%, down 5% on the week. Borrow availability is exceptionally wide at 2,769% — meaning there are far more shares available to lend than there are currently shorted — so there is no squeeze dynamic or borrow stress in the market. The short score, at 36.4, has drifted lower over the past two weeks, consistent with shorts gently reducing rather than adding. Options are a touch more cautious. The put/call ratio is running at 0.63, modestly above its 20-day average of 0.58 and about 1.4 standard deviations elevated. That is not alarming, but it does suggest some hedging activity has picked up alongside the price recovery — likely investors protecting gains into an event-heavy autumn rather than expressing an outright bearish view.
The institutional register is worth a brief note. Capital Research and Management holds 15.7% of shares outstanding and added 800,000 shares in the last reported period. Fidelity holds another 10.7% and added nearly 910,000 shares. Those are material top-up buys from long-only conviction holders — not momentum chasers. On the activist front, no 13D filer has emerged; all the Schedule 13G/A filings on record are passive in nature. One Vanguard entity filed an amended 13G showing its stake dropped to zero after previously holding 10%, while a separate Vanguard Capital Management entity filed at 5.35% — likely a restructuring of how those positions are reported internally rather than a genuine exit, though 13D/G disclosures around the 5% threshold are event-driven and positions are as last disclosed.
Valuation has re-rated meaningfully alongside the price move. The P/E has compressed by roughly 3.6 points over the past 30 days to around 20.9x, and price-to-book has fallen nearly 2 points to 9.8x. EV/EBITDA is around 21x. Those are not cheap multiples for a name with the earnings volatility ALNY has shown this year, but they are well below where the stock was trading before the summer selloff. The factor picture is mixed: EPS momentum ranks in the 40th to 43rd percentile range across 30- and 90-day windows, and EPS surprise sits in the 22nd percentile — not a name known for beating expectations right now. The short score rank, at the 60th percentile, flags the stock as carrying a bit more short-side attention than average, but nothing extreme.
Among peers, MDGL gained 5.2% on the week and MBRX added 6.4%, while INCY and ABBV both pulled back modestly. ALNY's 2.5% weekly gain sits roughly in the middle of that group — the stock is moving broadly with the biotech tape rather than leading or lagging conspicuously. The next material test is the October 29 earnings print, where the question will be whether AMVUTTRA franchise momentum has stabilised enough to close even part of the gap between the current price and the Street's still-elevated target range.
See the live data behind this article on ORTEX.
Open ALNY on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
